Last €12.95 EUR
Change Today -0.40 / -3.00%
Volume 0.0
IM8N On Other Exchanges
As of 2:08 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

insmed inc (IM8N) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/16/14 - €16.03
52 Week Low
08/13/13 - €7.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INSMED INC (IM8N)

insmed inc (IM8N) Related Bloomberg News

View More Bloomberg News

insmed inc (IM8N) Related Businessweek News

No Related Businessweek News Found

insmed inc (IM8N) Details

Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing inhaled therapies for patients with serious lung diseases. Its lead product candidate is ARIKAYCE, an inhaled antibiotic treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections. The company’s ARIKAYCE is in Phase II clinical trial for patients with lung infections caused by non-tuberculous mycobacteria (NTM) in the United States and Canada; and completed a Phase III clinical trial in Europe and Canada for cystic fibrosis (CF) patients who have lung infections caused by Pseudomonas aeruginosa. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.

61 Employees
Last Reported Date: 03/6/14
Founded in 1999

insmed inc (IM8N) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $445.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $330.0K
Chief Commercial Officer
Total Annual Compensation: $288.8K
General Counsel and Corporate Secretary
Total Annual Compensation: $149.9K
Special Advisor To Chief Executive Officer
Total Annual Compensation: $422.2K
Compensation as of Fiscal Year 2013.

insmed inc (IM8N) Key Developments

Insmed Incorporated Enters into Commercialization Agreement with PARI Pharma GmbH for the Manufacture and Supply of eFlow Nebulizer Systems and Related Accessories

On July 8, 2014, Insmed Incorporated entered into a Commercialization Agreement with PARI Pharma GmbH for the manufacture and supply of eFlow nebulizer systems and related accessories as optimized for use with the company's proprietary liposomal amikacin for inhalation. The agreement has an initial term of fifteen (15) years from the first commercial sale of the Device. The term of the agreement may be extended by the company for an additional five (5) years by providing written notice to PARI at the least one (1) year prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the agreement prior to the commencement of the Initial Term. The agreement allows for termination by either party upon the occurrence of certain events, including (i) the material breach by the other party of any provision of the agreement, (ii) the default or bankruptcy of the other party, or (iii) upon termination by the company of the license agreement between the parties.

US FDA Grants Insmed Incorporated's ARIKAYCE Breakthrough Therapy Designation for the Treatment of Adult Patients with Nontuberculous Mycobacterial

Insmed Incorporated announced that the U.S. Food and Drug Administration granted ARIKAYCE, or liposomal amikacin for inhalation, Breakthrough Therapy Designation for the treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease who are treatment refractory. This designation is based on findings from the Company's U.S. phase 2 clinical trial of ARIKAYCE to treat NTM lung infections. The Company has plans to meet with the FDA to discuss the regulatory pathway for ARIKAYCE.

Insmed Incorporated Presents at JMP Securities Healthcare Conference, Jun-24-2014 01:30 PM

Insmed Incorporated Presents at JMP Securities Healthcare Conference, Jun-24-2014 01:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: William H. Lewis, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM8N:GR €12.95 EUR -0.40

IM8N Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IM8N.
View Industry Companies

Industry Analysis


Industry Average

Valuation IM8N Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSMED INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at